Loperamide
- Generic Name
- Loperamide
- Brand Names
- Diamode, Imodium, Imodium Multi-symptom Relief
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33ClN2O2
- CAS Number
- 53179-11-6
- Unique Ingredient Identifier
- 6X9OC3H4II
- Background
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as diphenoxylate and haloperidol. Due to pharmacologic...
- Indication
Loperamide is indicated for the relief of diarrhea, including Travelers’ Diarrhea. As an off-label use, it is often used to manage chemotherapy-related diarrhea.
- Associated Conditions
- Diarrhea, Traveler's Diarrhea
- Associated Therapies
- -
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 563
- Registration Number
- NCT02400476
- Locations
- 🇺🇸
Compassionate Care Research Group Inc., Riverside, California, United States
🇺🇸Emad Ibrahim, M.D., Inc., Redlands, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Santa Ana, California, United States
Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 217
- Registration Number
- NCT02340481
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study
- Conditions
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02266849
- Locations
- 🇩🇰
Odense University Hospital, Surgical Department A, Odense, Denmark
Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02263365
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251119
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Rocky Mountain MS Research Group, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT02217982
- Locations
- 🇺🇸
Rocky Mountain MS Research Group, Salt Lake City, Utah, United States
Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents
- Conditions
- Interventions
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- University Hospital, Linkoeping
- Registration Number
- NCT02165475
- Locations
- 🇸🇪
Pelvic floor unit, University hospital of Linköping, Linköping, Sweden
Novel Topical Therapies for the Treatment of Genital Pain
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 9
- Registration Number
- NCT02099006
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- NICHD Pelvic Floor Disorders Network
- Target Recruit Count
- 300
- Registration Number
- NCT02008565
- Locations
- 🇺🇸
Kaiser San Diego, San Diego, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Duke University, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.